Viridian Therapeutics, Inc./DE Tax Withholding Paid on Stock Awards
Viridian Therapeutics, Inc./DE (VRDN) reported Tax Withholding Paid on Stock Awards of $171.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-24.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2017-03-24
- Viridian Therapeutics, Inc./DE payment, tax withholding, share-based payment arrangement for the quarter ending 2016-12-31 was $110.00K.
- Viridian Therapeutics, Inc./DE payment, tax withholding, share-based payment arrangement for the quarter ending 2016-09-30 was $5.00K, a 70.59% decline year-over-year.
- Viridian Therapeutics, Inc./DE payment, tax withholding, share-based payment arrangement for the quarter ending 2016-06-30 was $30.00K, a 90.60% decline year-over-year.
- Viridian Therapeutics, Inc./DE payment, tax withholding, share-based payment arrangement for the quarter ending 2016-03-31 was $26.00K, a 3.70% decline year-over-year.
- Viridian Therapeutics, Inc./DE payment, tax withholding, share-based payment arrangement for fiscal 2016 was $171.00K, a 52.89% decline from fiscal 2015.
- Viridian Therapeutics, Inc./DE payment, tax withholding, share-based payment arrangement for fiscal 2015 was $363.00K.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2016-12-31 | $110.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-24 | $115.00K derived: sum of 2 quarters · filed 2017-03-24 | $145.00K derived: sum of 3 quarters · filed 2017-03-24 | $171.00K 10-K · filed 2017-03-24 |
| 2016-09-30 | $5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-26 | $35.00K derived: sum of 2 quarters · filed 2016-10-26 | $61.00K 10-Q · filed 2016-10-26 | $61.00K derived: sum of 4 quarters · filed 2017-03-24 |
| 2016-06-30 | $30.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $56.00K 10-Q · filed 2016-08-15 | $56.00K derived: sum of 3 quarters · filed 2017-03-24 | $73.00K derived: sum of 4 quarters · filed 2017-03-24 |
| 2016-03-31 | $26.00K 10-Q · filed 2016-05-16 | $26.00K derived: sum of 2 quarters · filed 2017-03-24 | $43.00K derived: sum of 3 quarters · filed 2017-03-24 | $362.00K derived: sum of 4 quarters · filed 2017-03-24 |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-24 | $17.00K derived: sum of 2 quarters · filed 2017-03-24 | $336.00K derived: sum of 3 quarters · filed 2017-03-24 | $363.00K 10-K · filed 2017-03-24 |
| 2015-09-30 | $17.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-26 | $336.00K derived: sum of 2 quarters · filed 2016-10-26 | $363.00K 10-Q · filed 2016-10-26 | |
| 2015-06-30 | $319.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $346.00K 10-Q · filed 2016-08-15 | ||
| 2015-03-31 | $27.00K 10-Q · filed 2016-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |